Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341480 | 0.85 | GABRG2 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL341245 | 0.83 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL342401 | 0.74 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL6620532 | 0.72 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2653685 | 0.72 | GABRG2 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2652503 | 0.71 | GABRG2 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL342539 | 0.71 | GABRG2 (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL6768905 | 0.70 | GABRG2 (0.40) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL341136 | 0.70 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL249110 | 0.70 | GABRG2 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149102-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2004-12-08 | — | — | EP | claimed |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-08-21 | — | — | US | claimed |
| US-6500828-B1 | TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LTD. (GB) | 2002-12-31 | — | — | US | claimed |
| EP-1149102-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-31 | — | — | EP | claimed |
| WO-2000044752-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-03 | — | — | WO | claimed |
| EP-1149102-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-08-21 | — | — | US | disclosed |
| US-6500828-B1 | TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LTD. (GB) | 2002-12-31 | — | — | US | disclosed |
| EP-1149102-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044752-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABBR1, GABRA3, GABRA5 | GABRA1 7/4885GABRG2 15/4885GABRB3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.